-
Thematic Analysis
NewTelecom Services Sector Scorecard, Q1 2024 Update – Thematic Intelligence
The thematic screen of GlobalData’s telecom services sector scorecard has shown little sign of change in the first quarter of 2024. The top 10 is the same as it was in Q4 2023, with Telefónica in the top spot ahead of Orange and SK Telecom. Rounding out the top 10 are two US companies (Verizon and AT&T), two European companies (Deutsche Telekom and BT), two Middle Eastern companies (E& and Saudi Telecom), and one Japanese company (NTT).
-
Thematic Analysis
NewGaming Sector Scorecard, Q1 2024 Update – Thematic Intelligence
Tencent remains on top of the thematic screen of GlobalData’s gaming sector scorecard. It scores 5 out of 5 across six of the 10 themes that matter most in this market, including mobile gaming, social media, ecommerce, esports, game development, and China impact. It scores 4 out of 5 for the artificial intelligence (AI), metaverse, and cloud gaming themes. The only theme in which Tencent does not score well is regulation, but it is far from alone. All gaming companies...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Denileukin Diftitox in Cutaneous T-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Denileukin Diftitox in Cutaneous T-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Denileukin Diftitox in Cutaneous T-Cell Lymphoma Drug Details: Denileukin...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – 800 TCR in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 800 TCR in Metastatic Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 800 TCR in Metastatic Renal Cell Carcinoma Drug Details:...
-
Sector Analysis
NewMale Toiletries Market Opportunities, Trends, Growth Analysis and Forecast to 2028
Male Toiletries Market Report Overview The male toiletries market size was estimated at $17.9 billion in 2023 and is likely to grow at a CAGR of more than 3% from 2023 to 2028. The rising consumer interest in male grooming and hygiene is supporting sales in the sector. Furthermore, growing health and wellness concerns have created a demand for natural claims in male toiletries. The global male toiletries sector is also benefiting from the rising urban population and changing consumer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in T-Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Polatuzumab Vedotin in T-Cell Lymphomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Polatuzumab Vedotin in T-Cell Lymphomas Drug Details: Polatuzumab vedotin (Polivy /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Drug Details: Polatuzumab vedotin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Polatuzumab Vedotin in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Polatuzumab Vedotin in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Polatuzumab Vedotin in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Polatuzumab Vedotin in Primary Mediastinal B-Cell Lymphoma Drug Details:...